Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  FUJIFILM Holdings Corp    4901   JP3814000000

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Fujifilm : Kyowa Kirin Biologics announces Marketing Authorisation Application for FKB327 accepted for review by European Medicines Agency.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2017 | 08:42am CEST

May 22, 2017

FUJIFILM Corporation
Kyowa Hakko Kirin Co., Ltd.

FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (President & CEO: Hideaki Nomura; 'Fujifilm Kyowa Kirin Biologics') announces that on May 18, 2017, the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application (MAA) for FKB327, an adalimumab biosimilar candidate to the fully human anti-TNF-α*monoclonal antibody, Humira®.

In December 2014, Fujifilm Kyowa Kirin Biologics began a Phase 3 global clinical study of FKB327 at sites in the US, Europe and other countries to compare the efficacy and safety profile of FKB327 with Humira®(reference product) in patients with moderate to severe rheumatoid arthritis**. In this study, FKB327 met the primary endpoint and prespecified criteria for equivalence, and there were no significant differences in the rate of adverse events between FKB327 and Humira®. Based on the top-line results, announced on October 19, 2016, Fujifilm Kyowa Kirin Biologics decided to file the MAA for FKB327 to EMA in April 2017.

'We are delighted that EMA has accepted the application,' said Hideaki Nomura, President & CEO of Fujifilm Kyowa Kirin Biologics. 'The acceptance of this filing brings us one step closer to meeting the demand for high quality and affordable biopharmaceuticals.'

Fujifilm Kyowa Kirin Biologics was established by FUJIFILM Corporation (President & COO: Kenji Sukeno; 'Fujifilm') and Kyowa Hakko Kirin Co., Ltd. (President and CEO: Nobuo Hanai; 'Kyowa Hakko Kirin') on March 27, 2012 as a company for the development, manufacture, and marketing of biosimilars.

Fujifilm Kyowa Kirin Biologics creates revolutionary production processes and reduces the production cost of biosimilars by merging the technologies in advanced production, quality control and analysis which Fujifilm has developed over many years through its photographic film business, with the proprietary technologies and know-how accumulated by Kyowa Hakko Kirin through its biopharmaceutical R&D and manufacture. As the results of this partnership, the goal of Fujifilm Kyowa Kirin Biologics is to develop and manufacture reliable, high quality, cost-competitive biosimilar products that it will commercialise in a timely manner. Through this strategy, Fujifilm Kyowa Kirin Biologics aims to attain a leading position in the expanding biosimilar market. For more information about Fujifilm Kyowa Kirin Biologics, please visit http://fujifilmkyowakirin-biologics.com/en/.

  • *TNF-α (tumor necrosis factor alpha) is a cytokine that is involved in inhibition of tumorigenesis and defense against infection. Overexpression of TNF-α is implicated in a range of inflammatory diseases, including rheumatoid arthritis and psoriasis.
  • **Rheumatoid arthritis is an inflammatory autoimmune disorder that affects the joints, in particular arms and legs. It typically results in painful joints and joint degeneration, leading to deterioration of the daily functional activities. The disease may also cause malaise as one of the general symptoms.

For enquiries on information in this media release, contact:

FUJIFILM Corporation
Corporate Communications Division
TEL: +81-3-6271-2000Kyowa Hakko Kirin Co., Ltd.
Corporate Communications Department
TEL: +81-3-5205-7205

Fujifilm Holdings Corporation published this content on 22 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 22 May 2017 06:42:09 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FUJIFILM HOLDINGS CORP
05/22 FUJIFILM : Kyowa Kirin Biologics announces Marketing Authorisation Application f..
05/16 FUJIFILM : Lens Market 2017 - Nikon, Carl Zeiss, Canon, Leica, Sigma, Rokinon, S..
05/15 FUJIFILM : Mezographic install a Screen Truepress Jet W3200UV HS 3.2 metre flatb..
05/14 FUJIFILM : Graphics Works boosts production and slashes turnaround times with in..
05/14 FUJIFILM : Demonstrating the integrated solution of roll-fed digital press + pos..
05/14 FUJIFILM : Direct Edge Media exceeds client's print quality expectations with Fu..
05/14 FUJIFILM : New firmware updates for FUJIFILM GFX 50S coming soon.
05/14 FUJIFILM : SDPS Poinçon finds marked improvement in performance with Onset X2 fr..
05/10 FUJIFILM : makes capital investment in the regenerative medicine venture, Regcel..
05/04 FUJIFILM : An Application for the Trademark "SONOSITE" Has Been Filed by Fujifil..
More news
Sector news : Office Equipment - NEC
01/31 TOSHIBA : Canon sees first profit gain in three years after medical unit acquisi..
01/20 CANON CONSIDERING INVESTMENT IN TOSH : Kyodo
2016DJJapan's Economy Grows Faster Than Expected
2016DJBANK OF JAPAN : Japanese Economy Likely Expanded on Stronger Exports
2016DJAsia Shares Slide
More sector news : Office Equipment - NEC
News from SeekingAlpha
03/03 Fujifilm's Long Transformation Process Heading In The Right Direction
03/03 FujiFilm's biologics unit prevails over AbbVie in UK over Humira dosing paten..
2016 SPREAD'S THE WORD : Valuation Differentials Present Opportunity
2016 WALL STREET BREAKFAST : Happy Anniversary To The U.S. Bull Market
2016 NIKKEI : Canon to buy Toshiba Medical for $6.2B
Advertisement
Financials ( JPY)
Sales 2017 2 379 743 M
EBIT 2017 -
Net income 2017 111 009 M
Finance 2017 324 820 M
Yield 2017 1,67%
P/E ratio 2017 16,43
P/E ratio 2018 13,88
EV / Sales 2017 0,75x
EV / Sales 2018 0,73x
Capitalization 2 114 597 M
More Financials
Chart FUJIFILM HOLDINGS CORP
Duration : Period :
FUJIFILM Holdings Corp Technical Analysis Chart | 4901 | JP3814000000 | 4-Traders
Full-screen chart
Technical analysis trends FUJIFILM HOLDINGS...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 5 049  JPY
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Shigenobu Inenaga Head-Finance, Accounting & Business Administration
Yuzo Toda Director & Chief Technology Officer
Norio Shibata Director, Executive Officer & Head-IT Systems
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORP-7.41%19 048
CANON INC14.90%45 499
SEIKO EPSON CORPORATIO..-6.15%8 352
BROTHER INDUSTRIES LTD14.88%6 060
KONICA MINOLTA INC-22.30%4 071
PITNEY BOWES INC.0.00%2 833
More Results